Capsulution is Starting In-vivo Tests at Charité

Formulation of a Hormone Compound for Tumor Therapy

21-Sep-2006

Capsulution NanoScience AG has begun with pre-clinical in-vivo tests of formulations of a hormone compound for tumor therapy. In collaboration with the Forschungseinrichtung für Experimentelle Medizin (FEM) at the Charité in Berlin, these tests investigate new kinds of depot formulations, which were developed on the basis of Capsulution's technology platform in cooperation with an unnamed American company. By demonstrating this new kind of depot formulations Capsulution plans to make another important step establishing its patented technology in the field of pharmaceutical development. According to the company, the results of already generated in-vitro tests have served as the foundation for a contract development of yet another innovative hormone formulation.

Upon successful conclusion of the tests, Capsulution and its partner are planning to further develop the product as fast as possible. Few contingency risks are expected on the way to regulatory approval of the finished formulations on the market. In contrast to the development of new chemical entities (NCE), the development of these formulations are based on active and excipient agents that have already been approved.

https://www.bionity.com/en/news/58067/capsulution-is-starting-in-vivo-tests-at-charite.html